The GLP Weekend25% off GLPs15% off automatically25% with any codeEnds Sunday 11:59 PM PTThe GLP Weekend25% off GLPs15% off automatically25% with any codeEnds Sunday 11:59 PM PTThe GLP Weekend25% off GLPs15% off automatically25% with any codeEnds Sunday 11:59 PM PTThe GLP Weekend25% off GLPs15% off automatically25% with any codeEnds Sunday 11:59 PM PTThe GLP Weekend25% off GLPs15% off automatically25% with any codeEnds Sunday 11:59 PM PTThe GLP Weekend25% off GLPs15% off automatically25% with any codeEnds Sunday 11:59 PM PTNEW Verify Your Product · test your vial at an approved lab and get the test cost back in store credit →Free gift on orders $300+ · choose GLP-3 RT 5MG, GHK-Cu 100MG, NAD+ 500MG or MOTs-C 10MGUse code WELCOME10 for 10% off your orderFREE FEDEX 2-DAY shipping on orders over $250!Military · Veterans · First Responders: Verify & Save →Same-day shipping now live from the US West Coast · order by 2:30 PM PT weekdays, 12:00 PM PT Saturday →NEW Verify Your Product · test your vial at an approved lab and get the test cost back in store credit →Free gift on orders $300+ · choose GLP-3 RT 5MG, GHK-Cu 100MG, NAD+ 500MG or MOTs-C 10MGUse code WELCOME10 for 10% off your orderFREE FEDEX 2-DAY shipping on orders over $250!Military · Veterans · First Responders: Verify & Save →
CBL-514 β€’ Research evidence

CBL-514 Endpoints: Primary, Secondary and Exploratory

Quick answerA CBL-514 study can measure several outcomes without giving them equal evidentiary weight. Identify the prespecified primary outcome, then interpret secondary and exploratory analyses within the study's testing plan.

Published November 14, 2026 Β· Disguised Alpha Β· Source-linked research guide

Research education only. These notes do not provide instructions for human use or establish that a supplier’s material is equivalent to a clinical study formulation.

Identify the question chosen in advance

The 2026 CBL-514 paper names a clinician-rated primary outcome and additional participant-rating and MRI outcomes.[1] Those measures describe different aspects of the study. A favorable result on one should not be relabeled as success on another.

FDA’s multiple-endpoints guidance explains why numerous comparisons can increase false-positive conclusions unless the analysis addresses multiplicity.[2] The useful question is not simply how many outcomes improved, but which claims the planned statistical testing can support.

Why choosing the best result afterward changes the question

Original illustration: imagine a research report containing ten outcome measurements at four visits. Highlighting whichever of the 40 comparisons looks strongest is a different exercise from evaluating one endpoint selected before the data were examined.

The selected finding may still be scientifically interesting. Its role is to generate a question for further work unless a valid testing plan gives it confirmatory support. Our suggested summary therefore labels each result as primary, secondary or exploratory using the source’s terminology.

A subgroup adds another layer. A result among participants with a particular baseline feature is not automatically the overall trial result. Record the subgroup definition, size and whether it was planned. A headline should not promote the subgroup conclusion beyond the evidence supplied.

Build a claim-to-endpoint map

For every sentence about CBL-514 performance, write the matching outcome name, visit, population and statistical status. This makes it easier to catch accidental substitutions: appearance for volume, regional measurements for total-body change, or exploratory analysis for the primary endpoint.

  • Primary: what decided the study’s main efficacy question?
  • Secondary: what additional questions were tested, and in what order?
  • Exploratory: what findings need confirmation?
  • Unreported: which planned measurements cannot be evaluated from the available document?

A strong review can describe promising exploratory work without presenting it as settled. It also avoids implying that a published clinical finding verifies the properties of a retail research vial.

Frequently asked questions

Are secondary endpoints unimportant?

No. They may provide valuable additional evidence, but their interpretation depends on the design, prespecification and testing plan.

Does a positive subgroup result prove the overall trial succeeded?

No. A subgroup analysis and the trial's primary analysis answer different questions.

Continue your CBL-514 research

Compare the original study evidence with the documentation for the specific material you are reviewing.

Sources and further reading

  1. Lorenc et al., 2026 CBL-514 Phase IIb publication
  2. FDA: multiple endpoints in clinical trials

Publisher disclosure: Disguised Alpha is a research-material supplier. This guide is an educational interpretation of the linked sources, not an independent clinical review or a statement of regulatory approval.

References describe the studies or methods identified in the text. They do not independently certify the composition, clinical suitability or performance of Disguised Alpha products.

βœ“
Loading...
25% offGLPs15% off automaticallyUse code GLP or any code for 25% off0days00hrs00min00secShop the sale  →Shop